Tags

Type your tag names separated by a space and hit enter

OnabotulinumtoxinA (botulinum toxin type-A) in the prevention of migraine.
Expert Opin Biol Ther 2010; 10(2):289-98EO

Abstract

IMPORTANCE OF THE FIELD

Migraine is a highly prevalent disorder with the potential to progress into a chronic disease. The disability and health effects associated with frequent episodes of migraine underscore the value of preventive pharmacotherapy.

AREAS COVERED IN THIS REVIEW

OnabotulinumtoxinA has been studied as a migraine preventive in numerous clinical trials and in a variety of subpopulations with migraine. Overall, results from the clinical trials are mixed. However, the largest and most recent parallel studies (n = 1330) conducted on subjects with chronic migraine achieved statistically significant efficacy on numerous endpoints including the primary endpoint of reduction of headache days.

WHAT THE READER WILL GAIN

This article reviews several clinical studies using onabotulinumtoxinA in migraine prevention and highlights some of the inherent difficulties defining study endpoints and outcomes that are relevant to clinician, patients, and regulatory agencies.

TAKE HOME MESSAGE

Clinical trials utilizing onabotulinumtoxinA as a preventive therapy for migraine has revealed mixed results. In part this reflects the inherent difficulties in study design such as defining different subpopulations of migraine sufferers and trial end points that are meaningful to patient populations. Recent studies of subjects with chronic migraine appear to have positive results. If confirmed this would be the first preventive medication indicated specifically for chronic migraine.

Authors+Show Affiliations

Headache Care Center, 3805 S. Kansas Expressway, Springfield, MO 65807, USA. rcady@banyangroupinc.com

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

20088719

Citation

Cady, Roger K.. "OnabotulinumtoxinA (botulinum Toxin type-A) in the Prevention of Migraine." Expert Opinion On Biological Therapy, vol. 10, no. 2, 2010, pp. 289-98.
Cady RK. OnabotulinumtoxinA (botulinum toxin type-A) in the prevention of migraine. Expert Opin Biol Ther. 2010;10(2):289-98.
Cady, R. K. (2010). OnabotulinumtoxinA (botulinum toxin type-A) in the prevention of migraine. Expert Opinion On Biological Therapy, 10(2), pp. 289-98. doi:10.1517/14712590903586221.
Cady RK. OnabotulinumtoxinA (botulinum Toxin type-A) in the Prevention of Migraine. Expert Opin Biol Ther. 2010;10(2):289-98. PubMed PMID: 20088719.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - OnabotulinumtoxinA (botulinum toxin type-A) in the prevention of migraine. A1 - Cady,Roger K, PY - 2010/1/22/entrez PY - 2010/1/22/pubmed PY - 2010/4/7/medline SP - 289 EP - 98 JF - Expert opinion on biological therapy JO - Expert Opin Biol Ther VL - 10 IS - 2 N2 - IMPORTANCE OF THE FIELD: Migraine is a highly prevalent disorder with the potential to progress into a chronic disease. The disability and health effects associated with frequent episodes of migraine underscore the value of preventive pharmacotherapy. AREAS COVERED IN THIS REVIEW: OnabotulinumtoxinA has been studied as a migraine preventive in numerous clinical trials and in a variety of subpopulations with migraine. Overall, results from the clinical trials are mixed. However, the largest and most recent parallel studies (n = 1330) conducted on subjects with chronic migraine achieved statistically significant efficacy on numerous endpoints including the primary endpoint of reduction of headache days. WHAT THE READER WILL GAIN: This article reviews several clinical studies using onabotulinumtoxinA in migraine prevention and highlights some of the inherent difficulties defining study endpoints and outcomes that are relevant to clinician, patients, and regulatory agencies. TAKE HOME MESSAGE: Clinical trials utilizing onabotulinumtoxinA as a preventive therapy for migraine has revealed mixed results. In part this reflects the inherent difficulties in study design such as defining different subpopulations of migraine sufferers and trial end points that are meaningful to patient populations. Recent studies of subjects with chronic migraine appear to have positive results. If confirmed this would be the first preventive medication indicated specifically for chronic migraine. SN - 1744-7682 UR - https://www.unboundmedicine.com/medline/citation/20088719/OnabotulinumtoxinA__botulinum_toxin_type_A__in_the_prevention_of_migraine_ L2 - http://www.tandfonline.com/doi/full/10.1517/14712590903586221 DB - PRIME DP - Unbound Medicine ER -